This randomized phase 2 study is assessing if chemotherapy plus immunotherapy is superior to immunotherapy alone for patients with operable MSI-H/dMMR gastric and/or gastroesophageal junction cancer
This randomized phase 3 trial explores the addition of radiotherapy to the usual treatment (chemotherapy) in patients with esophagus and stomach cancer with limited spread